证券代码：688161 证券简称：威高骨科 公告编号：2025-034 山东威高骨科材料股份有限公司 关于全资子公司对外投资设立合资公司的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 山东威高骨科材料股份有限公司（以下简称"公司"或"威高骨科"）的全 资子公司山东威高海星医疗器械有限公司（以下简称"威高海星"）拟与上海瓴 健远影企业管理合伙企业（有限合伙）（以下简称"瓴健远影"）和上海穹仪医疗 科技有限公司（以下简称"穹仪医疗"）共同投资设立山东威影智能医疗科技有 限公司（名称最终以工商行政管理部门核定为准，以下简称"合资公司"），注册 资本 5,000 万元人民币，其中威高海星以自有资金出资 2,450 万元人民币，占合 资公司注册资本的比例为 49%。 公司于 2025 年 8 月 26 日召开第三届董事会第十五次会议、第三届监事会第 十三次会议，审议通过了《关于全资子公司对外投资设立合资公司的议案》。 风险提示：合资公司尚未设立，相关业务尚未开展。如果协议所述的出资先 决条件未得到满足，存在合资公 ...

证券代码：688161 证券简称：威高骨科 公告编号：2025-031 | | | 人。 | | --- | --- | --- | | | | 第八条 董事长为公司的法定代表 | | | | 担任法定代表人的董事或者经理 | | 2 | 第八条 董事长为公司的法定代表人。 | 辞任的，视为同时辞去法定代表 人。 | | | | 法定代表人辞任的，公司将在法定 | | | | 代表人辞任之日起三十日内确定 | | | | 新的法定代表人。 | | | | 第九条 法定代表人以公司名义从 | | | | 事的民事活动，其法律后果由公司 | | | | 承受。 | | | | 本章程或者股东会对法定代表人 | | | | 职权的限制，不得对抗善意相对 | | 3 | 新增 | 人。 | | | | 法定代表人因为执行职务造成他 | | | | 人损害的，由公司承担民事责任。 | | | | 公司承担民事责任后，依照法律或 | | | | 者本章程的规定，可以向有过错的 | | | | 法定代表人追偿。 | | | 第九条 公司全部资产分为等额股份， | 第十条 股东以其认购的股份为限 | | 4 | 股东以其认购 ...

Group 1 - The core point of the article is that Weigao Orthopedics reported a slight decline in revenue for the first half of 2025, while net profit saw a significant increase [1] - The company's operating revenue for the first half of 2025 was 741 million yuan, representing a year-on-year decrease of 1.28% [1] - The net profit for the same period was 142 million yuan, showing a year-on-year growth of 52.43% [1] Group 2 - The company plans to distribute a cash dividend of 1 yuan per 10 shares (including tax), totaling 39.7286 million yuan [1] - This cash dividend distribution accounts for approximately 27.99% of the net profit attributable to shareholders for the first half of 2025 [1]

Group 1 - Business Development (BD) is a significant trend in the domestic medical device industry, with a notable increase in BD transactions for innovative drugs, reaching a total of $60.8 billion in the first half of the year, surpassing the total for 2024 [1] - The Chinese government is promoting the development of domestic medical devices, with a focus on high-end medical equipment and technologies such as medical robots and AI medical devices, as outlined in the announcement released in July 2025 [2] - There is a fundamental difference in the evaluation systems and investment models between innovative drugs and medical devices, with medical devices requiring more extensive market and academic investment for recognition in different markets [3] Group 2 - The current BD model for medical devices is not suitable for a simple license-out approach due to the high dependency on usage scenarios and the experience of practitioners, which complicates the management and control of subsequent clinical trials and registrations [4] - Although the current BD model for innovative drugs may not fit medical devices, there are still BD transactions occurring in the medical device sector, such as the joint venture established between China Medical Device Co., Ltd. and GE Healthcare China [5] - The recently published "Medical Device BD White Paper 2025" indicates that BD in the medical device sector encompasses various transaction activities, including technology licensing, joint development, and strategic investments, with a focus on the actual product deployment [6] Group 3 - The trend in medical device BD is shifting from single transactions to a more structured resource allocation system, with an increasing willingness among investors and partners to engage in the early stages of product development and registration [7]

Core Viewpoint - The research activity in the field of biomedical materials in China has been declining from 2014 to 2024, with a decrease in the number of related papers published from 258 to 152 [3]. Group 1: Definition and Overview - Biomedical materials are defined as high-tech materials used for diagnosing, treating, repairing, or replacing human tissues and organs, categorized by their applications such as bone, soft tissue, cardiovascular, and medical membrane materials [1]. Group 2: Research Trends - The number of papers published in the biomedical materials field has shown a downward trend, indicating a decrease in research interest over the years [3]. - As of July 2025, higher education institutions are the primary contributors to the literature in this field, with Tianjin University leading by publishing 102 related papers [5]. Group 3: Research Themes - Medical polymer materials are identified as a popular research theme within the biomedical materials sector, alongside composite materials [9]. - Biomedical engineering is recognized as a prominent research discipline in this field, with significant contributions from organic chemistry, metallurgy, and metal processing [11].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Weigao Orthopedics in the medical device industry, noting its current stock price and market capitalization [1][2] - As of August 15, Weigao Orthopedics closed at 31.3 yuan, with a PE ratio of 52.03 and a total market value of 12.52 billion yuan [1] - The average PE ratio for the medical device industry is 56.58, with a median of 39.97, positioning Weigao Orthopedics at the 86th rank within the industry [1][2] Group 2 - The company reported a revenue of 290 million yuan for Q1 2025, reflecting a year-on-year decrease of 16.59%, while net profit was 51.79 million yuan, showing a year-on-year increase of 48.37% [1] - The gross profit margin for Weigao Orthopedics stands at 63.68% [1] - The company holds a total of 371 patents, including 86 invention patents and 266 utility model patents, indicating a strong focus on innovation in orthopedic medical devices [1]

Core Viewpoint - Weigao Orthopedics' stock closed at 30.83 yuan, down 2.99%, with a rolling PE ratio of 51.25 times, and a total market value of 12.332 billion yuan [1] Company Summary - Weigao Orthopedics specializes in a wide range of orthopedic products, including spinal, trauma, joint, sports medicine, bone repair materials, tissue repair, and surgical instruments, making it a leading domestic orthopedic enterprise with the most comprehensive product variety [1] - The company holds a total of 371 patents, including 86 invention patents and 266 utility model patents [1] - For Q1 2025, the company reported revenue of 290 million yuan, a year-on-year decrease of 16.59%, and a net profit of 51.789 million yuan, a year-on-year increase of 48.37%, with a gross profit margin of 63.68% [1] Industry Summary - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, placing Weigao Orthopedics at the 87th position in the industry [1] - The industry average market value is 11.792 billion yuan, while the median is 5.679 billion yuan [2]

天眼查商业履历信息显示，山东威高骨科材料股份有限公司，成立于2005年，位于威海市，是一家以从 事专用设备制造业为主的企业。企业注册资本40000万人民币，实缴资本40000万人民币。公司法定代表 人为陈敏。 通过天眼查大数据分析，山东威高骨科材料股份有限公司共对外投资了19家企业，参与招投标项目533 次，知识产权方面有商标信息1条，专利信息342条，此外企业还拥有行政许可123个。 来源：金融界 金融界消息 截至2025年8月14日收盘，威高骨科（688161）报收于30.83元，下跌2.99%，换手率 0.88%，成交量3.51万手，成交金额1.09亿元。 资金流向方面，今日主力资金净流出2059.55万元，占比成交额18.81%。其中，超大单净流出962.85万 元、占成交额8.8%，大单净流出1096.69万元、占成交额10.02%，中单净流出流入518.66万元、占成交 额4.74%，小单净流入1540.88万元、占成交额14.07%。 威高骨科最新一期业绩显示，截至2025一季报，公司营业总收入2.90亿元、同比减少16.59%，归属净利 润5178.90万元，同比增长48.37%，扣非净利润4 ...

金融界消息 截至2025年8月13日收盘，威高骨科（688161）报收于31.78元，下跌1.33%，换手率 0.96%，成交量3.84万手，成交金额1.22亿元。 通过天眼查大数据分析，山东威高骨科材料股份有限公司共对外投资了19家企业，参与招投标项目532 次，知识产权方面有商标信息1条，专利信息342条，此外企业还拥有行政许可123个。 资金流向方面，今日主力资金净流出1497.04万元，占比成交额12.31%。其中，超大单净流出582.27万 元、占成交额4.79%，大单净流出914.76万元、占成交额7.52%，中单净流出流入712.11万元、占成交额 5.86%，小单净流入784.92万元、占成交额6.46%。 来源：金融界 威高骨科最新一期业绩显示，截至2025一季报，公司营业总收入2.90亿元、同比减少16.59%，归属净利 润5178.90万元，同比增长48.37%，扣非净利润4906.69万元，同比增长41.95%，流动比率5.135、速动比 率4.321、资产负债率19.07%。 天眼查商业履历信息显示，山东威高骨科材料股份有限公司，成立于2005年，位于威海市，是一家以从 事专用设备制 ...

Core Insights - The coronary artery stent market in China is projected to reach approximately $7.0 billion by 2024, with a year-on-year growth of 6.4% [5][6]. Market Overview - In 2023, 8.368 million patients were hospitalized for coronary heart disease, with 1.901 million undergoing PCI (Percutaneous Coronary Intervention), where stent placement accounted for 81.2% of these procedures [3][6]. Product Structure - Drug-eluting stents (DES) dominate the market, expected to account for 69% of market revenue in 2024. The increasing prevalence of hypertension and diabetes due to aging populations and lifestyle changes is driving demand for DES [7][6]. Development Trends - **Material Innovation**: New alloy materials such as platinum-chromium and nickel-titanium are increasingly used due to their superior mechanical properties and biocompatibility. Biodegradable materials like polylactic acid and polycaprolactone are also being adopted to mitigate long-term foreign body reaction risks [11]. - **Functional Innovation**: Improvements in drug carriers for drug-eluting stents enhance drug release efficiency, reducing the risk of late thrombosis. Smart stents integrating sensors can monitor physiological parameters in real-time and adjust drug release accordingly [11].